EP1011644A4 - Verfahren und apparat zur behandlung der parkinson'schen krankheit - Google Patents

Verfahren und apparat zur behandlung der parkinson'schen krankheit

Info

Publication number
EP1011644A4
EP1011644A4 EP97944077A EP97944077A EP1011644A4 EP 1011644 A4 EP1011644 A4 EP 1011644A4 EP 97944077 A EP97944077 A EP 97944077A EP 97944077 A EP97944077 A EP 97944077A EP 1011644 A4 EP1011644 A4 EP 1011644A4
Authority
EP
European Patent Office
Prior art keywords
disease
methods
treating parkinson
parkinson
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97944077A
Other languages
English (en)
French (fr)
Other versions
EP1011644A1 (de
Inventor
Moshe Kushnir
Eliahu Heldman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Analyst Research Laboratories
Neuroderm Ltd
Original Assignee
ANALYST RESEARCH LABORATORIES
ANALYST RES LAB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ANALYST RESEARCH LABORATORIES, ANALYST RES LAB filed Critical ANALYST RESEARCH LABORATORIES
Publication of EP1011644A1 publication Critical patent/EP1011644A1/de
Publication of EP1011644A4 publication Critical patent/EP1011644A4/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
EP97944077A 1996-10-13 1997-10-09 Verfahren und apparat zur behandlung der parkinson'schen krankheit Withdrawn EP1011644A4 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL11941796A IL119417A (en) 1996-10-13 1996-10-13 Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
IL11941796 1996-10-13
PCT/IL1997/000327 WO1998016208A1 (en) 1996-10-13 1997-10-09 Methods and apparatus for treatment of parkinson's disease

Publications (2)

Publication Number Publication Date
EP1011644A1 EP1011644A1 (de) 2000-06-28
EP1011644A4 true EP1011644A4 (de) 2006-02-08

Family

ID=11069375

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97944077A Withdrawn EP1011644A4 (de) 1996-10-13 1997-10-09 Verfahren und apparat zur behandlung der parkinson'schen krankheit

Country Status (6)

Country Link
EP (1) EP1011644A4 (de)
JP (2) JP2002513389A (de)
AU (1) AU4570297A (de)
CA (1) CA2268455C (de)
IL (1) IL119417A (de)
WO (1) WO1998016208A1 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease
US6746688B1 (en) 1996-10-13 2004-06-08 Neuroderm Ltd. Apparatus for the transdermal treatment of Parkinson's disease
AU1681799A (en) * 1997-12-17 1999-07-05 Sekisui Chemical Co., Ltd. Percutaneously absorbable levodopa-containing preparation
WO2001001962A1 (en) * 1999-07-05 2001-01-11 Idea Ag. A method for the improvement of transport across adaptable semi-permeable barriers
US7858112B2 (en) 2002-02-28 2010-12-28 Lintec Corporation Percutaneous absorption system and percutaneous absorption method
JP4608187B2 (ja) * 2002-02-28 2011-01-05 リンテック株式会社 経皮吸収型製剤
DE10261807A1 (de) * 2002-12-19 2004-07-01 Turicum Drug Development Ag Deuterierte Catecholaminderivate sowie diese Verbindungen enthaltende Arzneimittel
US8815950B2 (en) 2003-08-29 2014-08-26 Janssen Biotech, Inc. Pharmaceutical compositions and method of using levodopa and carbidopa
AT500095B8 (de) * 2004-01-23 2007-02-15 Braun Werner Mag Transdermales abgabesystem
EP2007370B1 (de) * 2006-03-31 2013-12-18 Erasmus University Medical Center Rotterdam Neue zusammensetzung zur kontrolle des tumorwachstums
EP2640358B1 (de) * 2010-11-15 2018-01-03 Neuroderm Ltd Kontinuierliche verabreichtung von l-dopa, dopa-decarboxylase-inhibitoren, catechol-o-methyl-transferase-inhibitoren und zusammensetzungen dafür
BR112013014304A2 (pt) * 2010-12-10 2016-07-19 Synagile Corp composições de pró-fármaco levodopa infundíveis subcutaneamente e método de infusão
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
EP3075723B1 (de) * 2015-03-30 2017-05-24 Berlirem GmbH Höchlösliche l-dopa-glycerolester
DK3277660T3 (da) 2015-03-30 2020-01-27 Berlirem Gmbh Vandopløselige L-DOPA-estere
AU2016258179B2 (en) 2015-05-06 2021-07-01 Synagile Corporation Pharmaceutical suspensions containing drug particles, devices for their administration, and methods of their use
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009051A1 (en) * 1988-03-29 1989-10-05 Sandoz Ag Deprenyl for systemic transdermal administration
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
WO1995011016A1 (en) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2042520T3 (es) * 1986-06-10 1993-12-16 Chiesi Farma Spa Composiciones farmaceuticas que contienen el ester metilico de levodopa, preparacion y aplicaciones terapeuticas del mismo.
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
JPH04261119A (ja) * 1991-02-13 1992-09-17 Lintec Corp 経皮吸収型貼付剤
US5354885A (en) * 1992-12-24 1994-10-11 Yissum Research Development Company Of The Hebrew University Of Jerusalem Process for preparing ethyl ester of L-DOPA
IL119417A (en) * 1996-10-13 2003-02-12 Moshe Kushnir Pharmaceutical composition for transdermal administration of levodopa for parkinson's disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989009051A1 (en) * 1988-03-29 1989-10-05 Sandoz Ag Deprenyl for systemic transdermal administration
US4927408A (en) * 1988-10-03 1990-05-22 Alza Corporation Electrotransport transdermal system
WO1995011016A1 (en) * 1993-10-18 1995-04-27 Teva Pharmaceutical Industries Ltd. R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO9816208A1 *

Also Published As

Publication number Publication date
IL119417A (en) 2003-02-12
IL119417A0 (en) 1997-01-10
CA2268455C (en) 2007-05-15
EP1011644A1 (de) 2000-06-28
JP2002513389A (ja) 2002-05-08
AU4570297A (en) 1998-05-11
CA2268455A1 (en) 1998-04-23
WO1998016208A1 (en) 1998-04-23
JP2009001588A (ja) 2009-01-08

Similar Documents

Publication Publication Date Title
EP1011644A4 (de) Verfahren und apparat zur behandlung der parkinson'schen krankheit
EP0685963A3 (de) Bildverarbeitungsgerät und -verfahren.
EP1427482A4 (de) Verfahren und gerät für die aknebehandlung
EP0925046A4 (de) Topische zubereitungen und verfahren zur behandlung von hämorrhoiden
EP1272118A4 (de) Gerät zur behandlung des sphinkters
FR2777466B1 (fr) Appareil de traitement de tumeur
EP0715276A3 (de) Verfahren und Gerät zur Texturabbildung
EP1139398A4 (de) Verfahren und vorrichtung zur oberflächenbehandlung
EP1043276A4 (de) Verfahren und vorrichtung zur wasserbehandlung
EP1166597A4 (de) Tinnitusrehabilitationsgerät und verfahren
DE69528873D1 (de) Apparat zur Ultraschallbehandlung
EP1040443A4 (de) Verfahren und gerät zum illuminieren eines fingerabdrucks
EP1490050A4 (de) Verfahren zur behandlung von alzheimer und zur kognitiven verbesserung
EP0872266A4 (de) Spielgerät, -verarbeitungs- und -ausführungsmethode sowie spielsystem
NO990851D0 (no) Forbedret apparat for ultralyd-terapeutisk behandling
FR2680965B1 (fr) Appareil et procede pour le traitement de la peau.
EP0732729A3 (de) Plasmabearbeitungsgerät und -verfahren
BR9612228A (pt) Aparelho para o tratamento da exaustão em máquinas e método de utilização
DE69628852D1 (de) Therapeutische medizinische kleidung für narben und entsprechendes verfahren
BR9600969A (pt) Método de tratamento de doença inflamatória cardíaca
EP0979055A4 (de) Vorrichtung und verfahren zur auswertung von muskelfunktionen
EP0686941A3 (de) Verfahren und Vorrichtung zur graphischen Verarbeitung
EP1024697A4 (de) Verfahren zur behandlung von alzheimerschen krankheit
DE69604228D1 (de) Pupillen Messanordnung und Alzheimer Krankheits Diagnosesystem
EP1011073A4 (de) Musterextrahierungsgerät

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990512

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): BE DE FR GB IT NL

A4 Supplementary search report drawn up and despatched

Effective date: 20051223

17Q First examination report despatched

Effective date: 20060707

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: NEURODERM LTD.

Owner name: ANALYST RESEARCH LABORATORIES

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100504